The current status of hematopoietic cell transplantation.
about
Acute Myeloid Leukemia: A Concise ReviewDonor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activityIdentification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivityAntibody- and aptamer-strategies for GvHD prevention.Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol.UK experience of liver transplantation for erythropoietic protoporphyria.Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?CCR2 is required for CD8-induced graft-versus-host disease.Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.How and when should we monitor chimerism after allogeneic stem cell transplantation?Bioengineered Lacrimal Gland Organ Regeneration in Vivo.Current and emerging therapies for the lysosomal storage disorders.Recent advances in haematology and oncology: graft-versus-host disease, classification and treatment of non-Hodgkin's lymphomas, and sentinel-node biopsy in breast cancer.Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.Extrathymic development of murine T cells after bone marrow transplantationA review of transfusion practice before, during, and after hematopoietic progenitor cell transplantationTargeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.Adoptive transfer of virus-specific and tumor-specific T cell immunityEffects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants.Consistency and construct validity of the Activity Card Sort (modified) in measuring activity resumption after stem cell transplantation.Cancer stem cells: relevance to SCTDurable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception?Life in limbo: experiences of Iranian hematopoietic stem cell transplantation recipient patients and nurses in a qualitative studySymptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.Cellular therapy for repair of cardiac damage after acute myocardial infarctionHuman diversity of killer cell immunoglobulin-like receptors and disease.A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.Preservation of Antigen-Specific Functions of αβ T Cells and B Cells Removed from Hematopoietic Stem Cell Transplants Suggests Their Use As an Alternative Cell Source for Advanced Manipulation and Adoptive Immunotherapy.Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.National estimates of the use of hematopoietic stem-cell transplantation in children with cancer in the United States.Mechanism of tumor remission by cytomegalovirus in a murine lymphoma model: evidence for involvement of virally induced cellular interleukin-15.Analysis of multipotent mesenchymal stromal cells used for acute graft-versus-host disease prophylaxis.Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation.High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age.Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.Impact of C-rel inhibition of cord blood-derived B-, T-, and NK cells.A systematic approach to molecular quantitative determination of mixed chimaerism following allogeneic bone marrow transplantation: an analysis of its applicability in a group of patients with severe aplastic anaemia.
P2860
Q26766719-36A5441B-96A8-44CA-9013-B23E039700DEQ30558271-44A9F63C-2D7E-44AB-B045-2E6D1A8F22B8Q33573863-3C1009E0-A0EA-4495-931B-A532F0E553A1Q34196623-1996C7C5-4401-4078-8C24-91DE8666C098Q34885269-5D8C5B6A-9B7C-41AD-99DF-935506B529A6Q35003711-996178E2-0A17-4D3B-ACE4-596C369C5757Q35004685-3EE11FCF-DF84-468A-80B4-8BD633634029Q35205677-90EA7B69-A043-45BF-8E4B-5D4BD360D497Q35848441-961286B0-D841-4F5B-99C1-93958621F05DQ35849455-49002DD6-CA98-43A3-8436-6DF6C3B2F177Q35926907-A02A4D14-4DA7-4681-ACC5-45023927AF4AQ36138820-4C1C8B81-286B-4016-8BDF-05FA52C2CBC4Q36302871-630ADB80-2678-46F4-AA00-751A2A0D4C94Q36322963-8497AF10-99FE-4301-BA36-D012238B0D07Q36453843-95E1973A-085B-44C7-A48D-7E5CF6020C59Q36497976-6BD1FED4-2DFC-42FF-B492-3A30B7F677F1Q36941032-EE58212F-A5FD-45EC-86D2-CD018EC04118Q36994811-EAF32754-1583-42C9-BCFA-8EC870FF0462Q37287275-C5150A32-B7D2-4DB5-9B95-321037929203Q37291529-39F9199A-1006-43B7-BB79-8023F66A5137Q37362483-6E58345D-03E3-486C-87D1-F7C25C2DC1D4Q37398584-C480497C-420B-4A7B-9C9D-B063852BDC9EQ37484001-7C3B1071-959B-43DC-941B-90D96B2C35FAQ37552717-7F8BC69B-D561-4E50-8E2A-00743378AEF3Q37656904-E417667E-2661-407E-8E9E-B1E2125DF161Q37687140-20BDD99B-8514-45B6-B615-779F6948BA99Q37977062-972FD736-66D6-44FE-B6AF-94A0000F3D8FQ38572657-EF2D7FD2-19DD-49EE-88CC-9CF65F895F46Q40253951-488E215D-4F56-4301-BE8D-164B6C057005Q40395771-BB916B27-539D-4DCA-9B70-B0F5DB3ECC0EQ40408382-6971EA2E-2158-492E-9D85-FC4C03175224Q41387613-31DAA3FC-06BD-44CD-82AE-88AFE3352EABQ41638176-6EC10222-C415-43C5-BC98-0F6306B71EFEQ47416112-5BCCF972-E97A-4D9F-AB0A-980212DF62DDQ47928634-0C5510AB-2ED0-456E-9F95-28A5D7B40606Q50069823-5282F28F-489A-4712-AED0-46BB16086B74Q50762273-5387D45C-6D0A-4B37-AA93-DC2E8E7DB7E3Q51043186-6BA19B52-113F-4B7A-ADA4-402EF8B80B3DQ54707843-D122BB27-C6CC-4331-B602-927D50E3F9E5
P2860
The current status of hematopoietic cell transplantation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The current status of hematopoietic cell transplantation.
@ast
The current status of hematopoietic cell transplantation.
@en
The current status of hematopoietic cell transplantation.
@nl
type
label
The current status of hematopoietic cell transplantation.
@ast
The current status of hematopoietic cell transplantation.
@en
The current status of hematopoietic cell transplantation.
@nl
prefLabel
The current status of hematopoietic cell transplantation.
@ast
The current status of hematopoietic cell transplantation.
@en
The current status of hematopoietic cell transplantation.
@nl
P1476
The current status of hematopoietic cell transplantation.
@en
P304
P356
10.1146/ANNUREV.MED.54.101601.152456
P577
2001-12-03T00:00:00Z